This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo ...

The drug was made by Gilead and could help protect millions. President Trump addresses the nation after US attacks three ...

"This really has the possibility of ending HIV transmission," said Greg Millett, public policy director at The Foundation for ...

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

They grew it in an Israeli greenhouse, and it is now a 10-foot tree that produces a clear resin researchers say could be the biblical “balm of Gilead ... to a South Korean pastor convicted ...

The U.S. drugmaker has “mutually agreed” to terminate its collaboration and license agreement with South Korean biotech Yuhan for a pair of MASH therapies. It means Gilead has lost the $15 ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.